In the matter of the Canadian Anti-Doping Program;

And in the matter of an anti-doping rule violation by Justin Flores asserted by the Canadian Centre for Ethics in Sport;

File Outcome Summary

Summary

- 1. The Canadian Centre for Ethics in Sport (CCES) conducted an In-Competition Sample collection session on March 29, 2025, in Edmonton, AB.
- 2. Justin Flores ("the Athlete") was selected for Doping Control. The Sample provided by the Athlete returned an Adverse Analytical Finding (AAF) for Amfetamine, a non-Specified Substance included on the World Anti-Doping Agency's (WADA) 2025 Prohibited List.
- 3. Following receipt of the CCES's Notice of Charge letter asserting an anti-doping rule violation (ADRV) for the presence and Use of the above-mentioned Prohibited Substance, the Athlete failed to dispute the ADRV within the timelines specified in the letter, thereby admitting the ADRV, waiving his right to a hearing and accepting all applicable Consequences.

Jurisdiction

- 4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada and is responsible for handling the administration of the Canadian Anti-Doping Program (CADP), including providing anti-doping services to national Sport Organizations and their members.
- 5. As Canada's National Anti-Doping Organization, the CCES is compliant the World Anti-Doping Code ("the Code") and its mandatory International Standards. The CCES has implemented the Code and the International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
- 6. The Athlete is a member of and participates in the activities of Canada Powerlifting (CANPL). According to CADP Rule 1.3, the CADP provisions apply to all members of and Participants in activities of adopting Sport Organizations. The CADP was issued for adoption by Canadian Sport Organizations on October 26, 2020. CANPL adopted the CADP on October 29, 2020. Therefore, as a Participant in CANPL activities, the Athlete is subject to the CADP.

Doping Control

- 7. On March 29, 2025, the CCES conducted an In-Competition Sample collection session in Edmonton, AB. Testing was conducted as part of the CCES's domestic test distribution plan under the CADP.
- 8. The Athlete was notified that he had been selected for Doping Control and, with the Doping Control Officer from the CCES, completed the Sample collection process. The Athlete's Sample code number was 8071018.

Results Management

- 9. On April 2, 2025, the Athlete's Sample was received for analysis by the INRS Centre Armand-Frappier Santé Biotechnologie ("the INRS") in Laval, QC, a WADA-accredited laboratory.
- 10. The AAF was reported by the INRS on April 22, 2025. The Certificate of Analysis indicated the presence of Amfetamine.
- 11. Amfetamine is classified as a non-Specified Substance on WADA's 2025 Prohibited List and is Prohibited in-competition only.
- 12. On May 5, 2025, the CCES commenced an initial review of the matter and sent a letter to the Athlete, through CANPL, to determine whether the Athlete was eligible to apply for a retroactive Therapeutic Use Exemption (TUE).
- 13. On May 7, 2025, the Athlete responded to the CCES's Initial Review letter with their explanation.
- 14. On June 12, 2025, the CCES issued a Notification of a potential ADRV to the Athlete for the presence and Use of a Prohibited Substance and imposed a Provisional Suspension on the Athlete pursuant to CADP Rule 7.4.1.
- 15. On June 13, 2025, the Athlete responded to the CCES's Notification letter with their explanation.
- 16. On July 24, 2025, the CCES formally issued a Notice of Charge asserting an ADRV against the Athlete for the presence and Use of a Prohibited Substance.
- 17. In accordance with CADP Rule 10.2.1.1, the standard sanction for a violation involving a non-Specified Substance is a four (4) year year period of ineligibility. After reviewing all the information related to this case, the CCES acknowledged that the ADRV was unintentional, as the Athlete's Use of the Prohibited Substance was Out-of-Competition and in a context unrelated to sport performance.
- 18. The CCES therefore asserted a two (2) year period of Ineligibility in addition to all applicable Consequences in its Notice of Charge on July 24, 2025

Confirmation of Violation and Sanction

- 19. In accordance with CADP Rule 8.4.2, the CCES informed the Athlete in the Notice of Charge that a failure to dispute the asserted violation by August 13, 2025, would result in them being deemed to have admitted the violation, waiving their right to a hearing, and accepting the applicable Consequences.
- 20. On August 12, 2025, the CCES reminded the Athlete of their available options and the deadline to request a hearing as outlined in the Notice of Charge.

- 21. On August 14, 2025, the Athlete agreed to accept the two (2) year period of Ineligibility, after which the CCES extended the deadline to sign an Agreement on Consequences to August 26, 2025, and then once more to September 4, 2025.
- 22. The Athlete did not sign the Agreement of Consequences and failed to dispute the asserted violation by the applicable deadline; therefore, the Athlete was deemed to have admitted the violation, waived their right to a hearing, and to have accepted all applicable Consequences pursuant to CADP Rule 8.4.2.
- 23. Effective August 14, 2025, an ADRV was confirmed against the Athlete for the presence and Use of the identified Prohibited Substance.
- 24. In accordance with CADP Rule 10.2.2, the sanction for this violation is a two (2) year period of Ineligibility which, in accordance with CADP Rule 10.13.2.1, commenced on June 12, 2025, the date the Athlete was provisionally suspended, and concludes on June 11, 2027.
- 25. Further, in accordance with CADP Rules 9, 10.1 and 10.10, any competitive results obtained by the Athlete from date of Sample collection to the date the Athlete was provisionally suspended shall be Disqualified.
- 26. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 23rd day of September 2025.

Kevin Bean

Executive Director, Sport Integrity

CCES